Forbes Medi-Tech completes enrollment in cholesterol study

By Elaine Rigoli

Tampa, Fla., June 13 - Forbes Medi-Tech, Inc. said it has completed enrollment for the U.S. phase 2 trial of its cholesterol-lowering compound, FM-VP4.

To date, the company said there have not been any significant safety issues or concerns raised during the trial's progress.

The primary efficacy objective is to determine the effect of two doses of FM-VP4, 450 mg and 900 mg, given for 12 weeks, compared to a placebo, on low-density lipoprotein-cholesterol (LDL-C).

The goal of this trial is to demonstrate a minimum of 15% reduction from baseline in LDL-C at week 12.

The trial is expected to be completed by the end of the third quarter of 2006 with results anticipated to be released by year-end.

Vancouver, B.C.-based Forbes Medi-Tech is a life-sciences company dedicated to the development of products for the prevention and treatment of cardiovascular disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.